The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
32
No.
39
November 03, 2006
- Lung Screening Advocates Say Verdict’s In, Attack NCI Randomized Trial As “Outdated.”
- NEJM Paper Ignites Debate Over Spiral CT Scans For Lung Cancer.
- Interview with Claudia Henschke: Observational Study Of Spiral CT Should Change Medical Practice, She Says.
- PI Defends NCI’s National Lung Screening Trial As “Rigorous” Randomized Trial.
- Overdiagnosis Can Result In Harm To Patients, Experts Say.
TCL
Vol.
32
No.
41
November 17, 2006
- NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives
- NCI Seeks $5.799 Billion In FY08 Bypass Budget
- Advisors Approve New Grant Programs In Breast Pre-Malignancy, Lung Inflammation
- Braun Named Executive Director Of ASCO Foundation
- Leyland-Jones Named Director of Emory’s Winship Cancer Institute
- Simons Named CEO of Prostate Cancer Foundation.
TCL
Vol.
32
No.
42
November 22, 2006
- Scientists, Advocates Voice Objections To von Eschenbach’s Conflicts, 2015.
- Cancer Leadership Council Letter Calls For Permanent Leadership of NCI and FDA.
- Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.
- Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.
CCL
Vol.
29
No.
11
November 24, 2006
- FDA Approves Silicone Gel Breast Implants, Requires 10 Years Of Patient Follow-Up
- Study Identifies Women Likely To Benefit From Therapy With Aromatase Inhibitors
- Report Urges Heated Chemo To Optimize Patient Survival
- Some Long-Term Survivors At Higher Risk Of Stroke
- Lenalidomide, An Altered Thalidomide, Shows Promise
- Book Offers Info For Women Considering Ovary Removal
- NCI-Approved Clinical Trials
TCL
Vol.
32
No.
43
December 01, 2006
- Von Eschenbach Candidacy for FDA Hampered By Three Republican Holds.
- Acting Commissioner Tells Grassley He Supports “Academic Freedom” at The Agency, but “At A Proper Time.”
- Also: Court Will Reconsider Ruling on Access To Experimental Drugs.
- Judge Declines To Issue Injunction To Stop Amgen’s “Bundling.”
